SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Mudcat who wrote (30136)1/11/2000 9:17:00 PM
From: Torben Noerup Nielsen  Respond to of 32384
 
Mudcat,

Let me simplify this a bit. Arm I and Arm II are there to keep the statisticians happy and to do some more checking of Targretin side effects.

Arm III is the real trial.

Results for Targretin alone were comparable to those for Tamoxifen alone. It's the synergy. And if you recall the transcripts posted a few days ago, at least one of the members of the OAB is into biostatistics in a bad way....

Cheers, Torben